Blue Jet Healthcare Limited (BLUEJET) AI Stock Analysis

• Market Cap: ₹86.88B
• Dividend Yield: 0.22%
• Average Volume (3M): 19.19K
• Price to Earnings (P/E): 24.7
• Beta (1Y): 0.93
• Revenue Growth: 63.34%
• EPS Growth: 109.89%
• Country: IN
• Employees: 447
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 3.00
• Shares Outstanding: 173,465,420
• 10 Day Avg. Volume: 15,409
• 30 Day Avg. Volume: 19,187
• PEG Ratio: 0.55
• Price to Book (P/B): 12.87
• Price to Sales (P/S): 14.16
• P/FCF Ratio: -427.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹600.00
• Price Target Upside: -8.18% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: ₹592.00 ▼(-9.40% Downside)

Blue Jet Healthcare's overall stock score is driven by its strong financial performance, particularly in revenue growth and profitability. However, technical analysis indicates bearish momentum, and valuation metrics suggest moderate valuation with limited dividend yield. The absence of earnings call data and corporate events did not impact the score.

Positive Factors

Revenue Growth

The robust revenue growth of 45.01% indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Profitability

Improved net profit margin reflects efficient cost management and pricing power, enhancing the company's ability to generate sustainable profits.

Balance Sheet Health

Minimal leverage and high equity ratio indicate financial stability, reducing risk and enhancing the company's ability to invest in growth opportunities.

Negative Factors

Cash Flow Challenges

Negative free cash flow suggests difficulties in cash generation, potentially limiting the company's ability to fund operations and growth initiatives.

Cash Conversion Efficiency

Low cash conversion efficiency indicates challenges in converting profits into cash, which may affect liquidity and operational flexibility.

Lack of Earnings Call Data

The absence of earnings call insights limits transparency and investor understanding of management's strategic direction and future outlook.

Blue Jet Healthcare Limited Business Overview & Revenue Model

Company Description

Blue Jet Healthcare Limited (BLUEJET) is a dynamic player in the healthcare sector, focusing on the development and distribution of innovative medical products and services. The company operates primarily in the pharmaceuticals and medical devices sectors, offering a wide range of healthcare solutions designed to enhance patient care and operational efficiency in healthcare facilities. Core products include advanced medical devices, diagnostic tools, and a portfolio of pharmaceutical products aimed at addressing various health conditions.

How the Company Makes Money

BLUEJET generates revenue through multiple streams, including the sale of pharmaceutical products and medical devices to hospitals, clinics, and healthcare providers. The company also engages in long-term contracts with healthcare institutions for the supply of essential medical supplies, which provides a stable revenue base. Additionally, BLUEJET may collaborate with research organizations and healthcare providers to develop new products, often securing funding or revenue-sharing agreements as part of these partnerships. The company's focus on innovation allows it to stay competitive in the market, driving sales through both direct product offerings and strategic partnerships.

Blue Jet Healthcare Limited Financial Statement Overview

Summary

Blue Jet Healthcare exhibits strong financial performance with significant revenue growth and profitability, as evidenced by robust margins and a stable balance sheet with minimal leverage. However, challenges in free cash flow generation present a potential area of concern.

Income Statement

Blue Jet Healthcare has demonstrated strong financial performance with significant growth in total revenue from ₹7,103 million in 2024 to ₹10,299 million in 2025, reflecting a robust revenue growth rate of 45.01%. The gross profit margin improved to 55.24% in 2025, indicating efficient cost management. The net profit margin also increased to 29.65%, reflecting higher profitability. EBIT and EBITDA margins are solid at 49.30% and 41.18%, respectively. Overall, the income statement shows excellent growth and profitability.

Balance Sheet

The balance sheet of Blue Jet Healthcare reveals strong financial health with a low debt-to-equity ratio of 0.02, indicating minimal leverage. The equity ratio stands at 79.94%, showcasing a high level of financial stability. Return on equity (ROE) is impressive at 26.93%, reflecting effective use of equity to generate profits. The company's significant equity base and low debt level highlight its stability and low risk.

Cash Flow

Blue Jet Healthcare's cash flow performance is mixed. The operating cash flow to net income ratio is 0.15, suggesting lower cash conversion efficiency. However, the free cash flow to net income ratio is negative due to the decrease in free cash flow from ₹669 million in 2024 to -₹341 million in 2025, indicating challenges in generating free cash flow. While the company maintains positive operating cash flow, the pressure on free cash flow presents a potential area of concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	12.22B	10.30B	7.10B	7.18B	6.77B	4.94B
Gross Profit	6.32B	5.69B	3.89B	2.70B	2.97B	2.47B
EBITDA	4.88B	4.24B	2.48B	2.43B	2.69B	2.15B
Net Income	3.59B	3.05B	1.64B	1.60B	1.82B	1.38B
Balance Sheet
Total Assets	0.00	14.18B	10.59B	8.62B	7.13B	5.36B
Cash, Cash Equivalents and Short-Term Investments	3.06B	3.06B	3.09B	2.55B	1.81B	979.70M
Total Debt	0.00	199.86M	16.13M	68.31M	228.39M	516.15M
Total Liabilities	-11.33B	2.84B	2.14B	1.81B	1.92B	1.96B
Stockholders Equity	11.33B	11.33B	8.45B	6.81B	5.22B	3.40B
Cash Flow
Free Cash Flow	0.00	-341.15M	669.59M	822.79M	1.21B	807.67M
Operating Cash Flow	0.00	457.65M	2.41B	1.42B	1.46B	1.30B
Investing Cash Flow	0.00	-351.83M	-2.64B	-1.47B	-760.26M	-566.48M
Financing Cash Flow	0.00	-185.57M	-19.86M	-42.33M	-561.45M	-221.90M

Blue Jet Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 653.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLUEJET, the sentiment is Negative. The current price of 653.45 is above the 20-day moving average (MA) of 531.50, above the 50-day MA of 559.29, and below the 200-day MA of 725.17, indicating a bearish trend. The MACD of -13.44 indicates Positive momentum. The RSI at 31.68 is Neutral, neither overbought nor oversold. The STOCH value of 19.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BLUEJET.

Blue Jet Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPRIYA	75 Outperform	₹59.11B	32.41	―	0.13%	14.35%	15.79%
SYNGENE	71 Outperform	₹252.74B	53.77	―	0.19%	8.57%	-2.93%
BIOCON	63 Neutral	₹506.62B	95.62	―	0.12%	10.62%	-66.88%
JUBLINGREA	63 Neutral	₹109.29B	37.58	―	0.74%	3.80%	64.94%
BLUEJET	61 Neutral	₹86.88B	24.65	―	0.22%	63.34%	109.89%
CONCORDBIO	61 Neutral	₹138.18B	42.65	―	0.80%	3.63%	-1.21%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Blue Jet Healthcare Limited Corporate Events

Blue Jet Healthcare Confirms Compliance with SEBI Regulations

Blue Jet Healthcare Limited has announced that it has complied with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, as confirmed by its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. The company stated that all its shares are held in dematerialized form, and no requests for rematerialization were received during the quarter ended September 30, 2025, indicating streamlined operations and compliance with regulatory requirements.